American Association of Airport Executives' CEO Todd Hauptli Visits Implant Sciences US Airports' Association CEO impressed with QS-B220 product and Company's readiness as it nears completion of TSA testing for airport checkpoint screening
WILMINGTON, Mass., July 1, 2014 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that Todd Hauptli, President and Chief Executive Officer of the American Association of Airport Executives (AAAE) visited and toured the Company's headquarters and manufacturing facility.
"I am really impressed with the trajectory of the company at Implant Sciences," AAAE's President and CEO, Todd Hauptli, commented. Hauptli reviewed the QS-B220, currently in final stages of evaluation by the TSA, which was designed to advance the state of the art in system uptime, false alarms rates, and throughput—all things that will support getting travelers through checkpoints safely and quickly. "It is clear to me that the Company has put much thought into preparing its manufacturing and support teams to provide for the rapid deployment of a large number of these systems," said Hauptli.
The QS-B220 clears down rapidly both between samples as well as after an alarm, resulting in faster processing at checkpoints. The system's patented inCal™ internal automatic calibration system keeps the system ready to detect without operator intervention. Push button maintenance and diagnostics mean more consistent, longer uptimes to help ensure deployed systems are available for virtually continuous use.
"We had a great visit today with Todd and we thank him for taking the time to gain a deeper understanding of our technology and the value we seek to provide to aviation security. AAAE has long been a key stakeholder in US airport security operations and policy, continually working with TSA and policy makers to optimize security while improving the experience of air travelers," stated Implant Sciences' President and CEO, Glenn D. Bolduc.
"Implant Sciences is committed to delivering ETD systems, such as the QS-B220, that are purpose-built to meet the needs of critical safety as well as the operational and logistical needs of airports here in the US and internationally," Bolduc added. "With our membership in AAAE and this visit from Mr. Hauptli, we continue to gain critical input about what airports are looking for in next-generation aviation security technologies. This interaction with airport leadership is crucial to our current and future technology development."
AAAE is the world's largest professional organization for airport executives, representing thousands of airport management personnel at public-use commercial and general aviation airports. The organization's members represent approximately 850 airports and hundreds of companies and organizations that support airports. AAAE is also is one of the most influential associations in Washington DC, ranking in the top 1% of professional trade associations in terms of budget and staff size with an unparalleled reputation of influence and effectiveness in Washington for their outstanding advocacy and support of airports. Implant Sciences became a member of the AAAE in January.
The AAAE's Carter Morris recently interviewed Implant Sciences' Chief Operating Officer Dr. Bill McGann on its program, One on One. To see the video please visit: https://www.youtube.com/watch?v=K2Rg2g_WaMs
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 50 countries worldwide. Implant Sciences is only the third manufacturer, and the sole American-owned company, to currently have an ETD system named as a Qualified Product by the US Transportation Security Administration. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., STAC in France, the German Ministry of the Interior, and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland Security Award for "Best Explosives Detection Solution." All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation